Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia

Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia International Journal of Drug Policy 52 (2018) 16–19 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locat e/drugpo Short Report Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia a b b c Tamar Kikvidze , Niklas Luhmann , Elisabeth Avril , Maia Butsashvili , d b b a Konstantine Labartkava , Aurélie Etienne , Diane Le Pluart , Ina Inaridze , c a b, Ana Gamezardashvili , David Kharshiladze , Julie Bouscaillou Médecins du Monde Georgia, 46 Gutnis Street, Tbilisi, 0103, Georgia Médecins du Monde France, 62 rue Marcadet, 75018, Paris, France Clinic Neolab, 47 Tashkenti Street, Tbilisi, 0160, Georgia New Vector, 9 Mtskheta Street, Tbilisi, 0179, Georgia Background Sciences. The initial phase (2015–2016) of the NHCEP focused on providing 7000 free courses of Sofosbuvir (with Ribavirin+/ Eliminating hepatitis C PegInterferon) limited to persons with advanced liver fibrosis (F3 or more corresponding to elastometry above 10 kPa or FIB4 > 3.25). The introduction of new highly effective direct-acting antiviral The ongoing second phase(2016–2020) intends totreateveryperson (DAA) therapies has created an opportunity for the global chronically infected with HCV (Gvinjilia et al., 2016). To succeed in elimination of hepatitis C http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png International Journal of Drug Policy Elsevier

Loading next page...
 
/lp/elsevier/harm-reduction-based-and-peer-supported-hepatitis-c-treatment-for-8GLESjOB1L
Publisher
Elsevier
Copyright
Copyright © 2017 Elsevier B.V.
ISSN
0955-3959
D.O.I.
10.1016/j.drugpo.2017.11.014
Publisher site
See Article on Publisher Site

Abstract

International Journal of Drug Policy 52 (2018) 16–19 Contents lists available at ScienceDirect International Journal of Drug Policy journal homepage: www.elsevier.com/locat e/drugpo Short Report Harm reduction-based and peer-supported hepatitis C treatment for people who inject drugs in Georgia a b b c Tamar Kikvidze , Niklas Luhmann , Elisabeth Avril , Maia Butsashvili , d b b a Konstantine Labartkava , Aurélie Etienne , Diane Le Pluart , Ina Inaridze , c a b, Ana Gamezardashvili , David Kharshiladze , Julie Bouscaillou Médecins du Monde Georgia, 46 Gutnis Street, Tbilisi, 0103, Georgia Médecins du Monde France, 62 rue Marcadet, 75018, Paris, France Clinic Neolab, 47 Tashkenti Street, Tbilisi, 0160, Georgia New Vector, 9 Mtskheta Street, Tbilisi, 0179, Georgia Background Sciences. The initial phase (2015–2016) of the NHCEP focused on providing 7000 free courses of Sofosbuvir (with Ribavirin+/ Eliminating hepatitis C PegInterferon) limited to persons with advanced liver fibrosis (F3 or more corresponding to elastometry above 10 kPa or FIB4 > 3.25). The introduction of new highly effective direct-acting antiviral The ongoing second phase(2016–2020) intends totreateveryperson (DAA) therapies has created an opportunity for the global chronically infected with HCV (Gvinjilia et al., 2016). To succeed in elimination of hepatitis C

Journal

International Journal of Drug PolicyElsevier

Published: Feb 1, 2018

References

You’re reading a free preview. Subscribe to read the entire article.


DeepDyve is your
personal research library

It’s your single place to instantly
discover and read the research
that matters to you.

Enjoy affordable access to
over 18 million articles from more than
15,000 peer-reviewed journals.

All for just $49/month

Explore the DeepDyve Library

Search

Query the DeepDyve database, plus search all of PubMed and Google Scholar seamlessly

Organize

Save any article or search result from DeepDyve, PubMed, and Google Scholar... all in one place.

Access

Get unlimited, online access to over 18 million full-text articles from more than 15,000 scientific journals.

Your journals are on DeepDyve

Read from thousands of the leading scholarly journals from SpringerNature, Elsevier, Wiley-Blackwell, Oxford University Press and more.

All the latest content is available, no embargo periods.

See the journals in your area

DeepDyve

Freelancer

DeepDyve

Pro

Price

FREE

$49/month
$360/year

Save searches from
Google Scholar,
PubMed

Create lists to
organize your research

Export lists, citations

Read DeepDyve articles

Abstract access only

Unlimited access to over
18 million full-text articles

Print

20 pages / month

PDF Discount

20% off